Subject: RE: 11/2 FDA conference--virtual attendance

Subject: RE: 11/2 FDA conference--virtual attendance

Hi David,

I’m glad things are going well. You are welcome to tune in for the meeting on November 2, 2022. It will stream directly from this website: https://sczaction.org/insight-initiative/pfdd/ The live meeting will be from 10-3 and the recording of the meeting will be available on the same site immediately after the meeting concludes.

The meeting is open to the public, and we would love to have others tune in.

If you have any questions, please let me know. I hope you have a nice weekend!

Best,

Lauren

I will be a panelist on panel 1. —Dave Geiger

NOTE:

You’re Invited to Participate! “Save the Date” Link, Calendar Invite Now Available for Nov. 2 PFDD Meeting

A “Save the Date” link is now available that provides the information you’ll need to view the livestream of our Externally-Led Patient-Focused Drug Development meeting on schizophrenia on Nov. 2.

The virtual meeting, “Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive,”  will run from 10 am to 3 pm ET, and will feature two panels of people who live with schizophrenia and those who care for them. We’ll also have discussion sessions on key topics that you can participate in via phone and email. (You won’t be required to disclose your name.)

When you click on the Save the Date link, it also will take you to an Early Comments form on our website, which you can use to submit comments on a variety of questions about living with schizophrenia. We may choose your comments to share with other participants during the meeting, and they could be included in our Voice of the Patient Report to be published after the meeting. Again, this type of participation won’t require you to be personally identified.

This meeting is an important chance for our community to help the FDA, drug developers and healthcare providers better understand how schizophrenia affects our lives and what we need from drug treatments to help us thrive. Please save the meeting date on your calendar today! It’s time for our voices to be heard.

About the PFDD meeting

The Externally-Led Patient Focused Drug Development (PFDD) meeting – “Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive” – offers the chance for people living with schizophrenia and their family members to share their treatment needs and concerns with drug developers and FDA staff who review new drug applications. Many new treatments for schizophrenia are in development, making it more critical than ever for drug developers and reviewers to understand what treatment benefits people with schizophrenia expect – and what risks they may be willing to tolerate to achieve those benefits.

The virtual meeting will be co-hosted by the Schizophrenia & Psychosis Action Alliance, the American Foundation for Suicide Prevention, Mental Health America, the National Alliance on Mental Illness, and the National Council for Mental Wellbeing